Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Parasitol Int ; 98: 102822, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37940035

RESUMEN

Faced with the focal resurgence of onchocerciasis reported since 2004 in the South-West of Burkina Faso, the Neglected Tropical Diseases Control Program adopted a resumption of biannual community-directed treatment with ivermectin, since 2011 in the Cascades region and since 2013 in the South West region. The objective of this study was to assess the situation of onchocerciasis transmission in the Cascades region, nine years after the resumption of mass drug administration. This cross-sectional and descriptive survey concerned people over 5. The traditional method of skin snip on both iliac crests was performed for the parasitological diagnosis of onchocerciasis. The Ov-16 serological test was carried out in children aged 5 to 9 years. In 22 surveyed villages, the overall prevalence of microfilariae was 0.11% and below the tolerable threshold of 5%. It was less than 5% in all the villages (n = 22), less than 1% in 21 villages (99%) and zero in 19 villages (86.36%). The community microfilarial loads varied from 0.01 to 0.05 mf/b. Out of 946 children tested for OV-16, only one 9-year-old was positive and whose skin snip examination was negative. All the positive cases came from endemical areas in Côte d'Ivoire. Population migration is a risk factor for introducing the parasite into Burkina Faso; it also is risk factor for the effective elimination of onchocerciasis which requires the joint development of a control strategy between neighboring countries.


Asunto(s)
Oncocercosis , Niño , Animales , Humanos , Adulto Joven , Adulto , Oncocercosis/tratamiento farmacológico , Oncocercosis/epidemiología , Oncocercosis/prevención & control , Burkina Faso/epidemiología , Estudios Transversales , Ivermectina/uso terapéutico , Côte d'Ivoire , Prevalencia , Microfilarias
2.
Infect Drug Resist ; 16: 6673-6680, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37849789

RESUMEN

Purpose: Intermittent preventive treatment with sulfadoxine-pyrimethamine is widely used for the prevention of malaria in pregnant women in Africa. Known resistance cases of sulfadoxine-pyrimethamine during pregnancy need to be follow up to support IPTp implementation in Burkina Faso. However, data on the development and spread of resistance to this molecule are lacking. This study aimed to investigating the genetic diversity of P. falciparum and the mutation prevalence in the dhfr and dhps genes infected from postpartum infected placentas. Patients and Methods: This was a prospective and cross-sectional study conducted between April 2019 and March 2020 in four health districts of Ouagadougou capital city. From the placentas collected after delivery, P. falciparum detection and mps1 and msp2 polymorphism analysis were performed by nested PCR. The resistance profile was checked after analyzing the mutation point on dhfr and dhps genes. Results: PCR-positive samples were estimated at 96% for msp1 and 98% for msp2. The polymorphism analysis showed that the RO33 and 3D7 allelic families were the most widespread with 62.5% and 91.83%, respectively. Multiple infections by msp1 and msp2 were frequent with 12.50% and 92.92%, respectively. The prevalence of individual dhfr mutation point, 51I, 108A, and 59R, was 1.96, 15.68, and 7.84, respectively, and the dhps mutation point, 437G, was 3.92. There is no detected mutation at the point 164L and 540E. The triple (51I+108A+59R) in dhfr and quadruple (51I+108A+59R+ 437G) mutation were not found. Conclusion: The results showed that Plasmodium falciparum has a high genetic diversity of msp1 and msp2. This suggests that dhfr and dhps mutant genotypes are potential early warning factors in the increase in the sulfadoxine-pyrimethamine resistance.

3.
Ann Parasitol ; 67(3): 489-497, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34953124

RESUMEN

Pregnant women are the most vulnerable populations exposed to intestinal parasitoses. To develop strategies to fight against these infections, it is essential to carry out regular surveys in order to provide reliable epidemiological data on intestinal parasitoses in at-risk populations. A prospective cross-sectional study was carried out from February to April 2015 in pregnant women seen during the prenatal consultation. The study took place in 3 health centers located in Health District of Dafra at Bobo-Dioulasso in Burkina Faso. The parasitological examination consisted in carrying out a standard stool parasitological examination and the modified Ziehl Neelsen staining. A total of 315 stool samples were collected and analyzed. The overall prevalence of intestinal parasitosis was 66.7% [95% CI: 61.1­71.8] with prevalences of 60.9% in Bolomakot., 69.2% in Guimbi and 69.8% in Y.gu.r.sso. Protozoa were the most encountered with of 66.0% prevalence and 1.3% of helminths. The most common protozoa species were Entamoeba coli (36.2%), Giardia lamblia (16.2%), Entamoeba histolytica (14.9%), Cryptosporidium sp. (12.1%) and Trichomonas intestinalis (10.5%). The helminths were represented by Hymenolepis nana (0.6%), Strongyloides stercoralis (0.3%) and Dicrocoelium sp. (0.3%). The prevalence of intestinal parasitosis is very high in pregnant women and dominated by protozoa. Most recently, it has been shown that metronidazole can be administered at all ages of pregnancy at a dosage of 1 g/day for 5 days for the treatment of intestinal protozoa in pregnant women. It would therefore be essential to evaluate this strategy in Burkina Faso by administering metronidazole concomitantly with sulfadoxine-pyrimethamine.


Asunto(s)
Criptosporidiosis , Cryptosporidium , Parasitosis Intestinales , Animales , Burkina Faso/epidemiología , Estudios Transversales , Femenino , Humanos , Parasitosis Intestinales/epidemiología , Embarazo , Mujeres Embarazadas , Prevalencia , Estudios Prospectivos
4.
Med Mycol Case Rep ; 26: 10-12, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31667051

RESUMEN

Talaromycosis is endemic in Southeast Asia and is commonly described in HIV-infected patients. We describe the first case of Talaromycosis in HIV-infected patient in Burkina Faso. This is an 83-year-old man with skin lesions on the right foot. The thick scales were used for the mycological examination. Microscopic examination of growth allowed isolation of Talaromyces marneffei in its yeast and mold forms. The patient was treated successfully with Itraconazole (400 mg/day) for 8 weeks.

5.
Infect Drug Resist ; 12: 3859-3866, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31908500

RESUMEN

OBJECTIVE: Candida albicans is a yeast with multiple genotypes. It's a commensal fungus colonizing various sites. However, when the host's immune system weakens, it becomes pathogenic and is responsible for various lesions. In Burkina Faso, antifungal drugs are frequently used, particularly fluconazole, the most used systemic antifungal. This antifungal drug and other antifungal drugs are often used for self-medication or prescribed outside of antifungal susceptibility test results. These situations led to the emergence of Candida albicans strains resistant to antifungal drugs commonly used in Burkina Faso. The aim of this study was to determine the types of Candida albicans using PCRs targeting 25S rDNA and ALT repeat sequences of the RPS and to establish their azoles and polyenes susceptibility profile. MATERIAL AND METHODS: Antifungal susceptibility testing by disk diffusion method was performed in accordance with CLSI document M44-A for yeasts and the manufacturer's instructions. Candida albicans isolates were genotyped using specific PCR primers of the rDNA and RPS genes. RESULTS: Ten (10) RPS types of Candida albicans were found in our study: The most common RPS types are A3 (40.6%), A2 (24.0%) and A2/3 (14.6%) for genotype A, B2/3 (5.2%) for genotype B and C2 (3.2%) for genotype C. The Azole resistance, especially fluconazole (74.4%), was the most common with genotype A, including A3 (36.6%), A2 (18. 3%). Polyene resistance was rare with nystatin, only A3 (1.2%) resistant isolate to nystatin was observed. For amphotericin B, the highest observed resistance rates were A3 (11.0%) and A2/3 (8.5%) for the genotype A and B2 (10.0%), B3 (10.0%) and B2/3 (10.0%) for genotype B. CONCLUSION: Our study showed that Candida albicans resistance to azoles, especially to fluconazole, is an important phenomenon in Ouagadougou, and several genotypes RPS types are involved. Thus, fluconazole would not be an antifungal agent for first-line prescribing for treatment of candidiasis in Ouagadougou. This study will be continued to determine the molecular mechanisms involved in these antifungal resistances, for further research of new molecules with different action targets.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...